As β-AR antagonists with different degrees of IA had differential profiles in an animal model of asthma [155], it has been proposed that a combination of the choice of compounds with strong IA and slow up-titration of their dosages may lead to the effective and innovative management of asthma patients [156]. Here, ADRB2 is linked to asthma.